Vietnam Infectious Disease Drugs Market Analysis Report 2022 to 2030

Vietnam Infectious Disease Drugs Market Analysis

$ 3999

Vietnam Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.81 Bn by 2030 with a 4.5% CAGR. The industry is influenced by factors such as government healthcare programs, rising infectious disease prevalence, and technological improvements. The market is dominated by key players like Mekophar, Hau Giang Pharmaceutical, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.

ID: IN10VNPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Aneri Parekh

Buy Now

Vietnam Infectious Disease Drugs Market Executive Summary

Vietnam Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.81 Bn by 2030 with a 4.5% CAGR.

The development, production, marketing, and distribution of pharmaceuticals intended to control, prevent, or treat infectious diseases constitute the core activities of the Vietnam Infectious Disease Drugs Market. This market includes a broad spectrum of drugs that target diseases brought on by bacteria, viruses, parasites, and fungi, such as vaccines, antibiotics, antivirals, and antifungals. Vietnam faces serious health difficulties from infectious diseases such as tuberculosis, HIV/ AIDS, hepatitis, dengue fever, malaria, and respiratory infections, which have increased the need for efficient pharmaceutical treatments.

Factors such as the incidence of infectious diseases, healthcare infrastructure, regulatory policies, investments in research and development, and cooperation between pharmaceutical companies and healthcare providers are some of the elements that have an impact on the dynamics of your market. The infectious disease pharmaceuticals market plays a crucial role in resolving public health concerns and improving healthcare outcomes in Vietnam. This is due to the increasing burden of infectious illnesses, and there is also an increased emphasis on the accessibility and quality of healthcare in Vietnam.

The projected worth of the global market for drugs treating infectious disorders in 2023 was $118.75 Bn. Both an increase in diagnoses and government-sponsored public education efforts about the management and prevention of infectious diseases have contributed to this rise. The increasing level of generic competition is indicative of a changing market situation. Removing financial obstacles and expanding access to therapy are necessary for long-term progress, especially in developing nations. This will lead to more industrial research and development.

Mekophar, with a projected market share of almost 14% in 2023, is among the top five competitors in the Vietnamese pharmaceutical industry. Mekophar manufactures a broad variety of medications for infectious diseases, such as antivirals, antifungals, antiparasitics, and antibiotics. The company also produces vaccinations, medical supplies, and necessary medications. Mekophar plays an essential role in the Vietnamese people's ability to obtain necessary and reasonably priced medications.

Vietnam infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Technological Advancements: Medical science and technology have produced more effective and tailored infectious disease treatments. These drugs have better treatment outcomes and fewer adverse effects than earlier drugs, which boost growth in Vietnam.

Prevalence of Infectious Diseases: Vietnam is heavily affected by infectious diseases such as dengue fever, HIV/ AIDS, malaria, and tuberculosis. The risk of transmission rises with population growth and urbanization, which fuels the need for medications to treat and prevent these diseases.

Government Initiatives: To increase access to healthcare services, particularly the prevention and treatment of infectious diseases, the Vietnamese government has been putting in place many healthcare initiatives. These programs frequently entail greater financing for public health campaigns, the purchase of necessary medications, and healthcare infrastructure, all of which can propel the market for infectious disease medications upward.

Market Restraints:

Regulatory Obstacles: Strict rules and lengthy approval procedures could prevent innovative medications from entering the market sooner than they should, giving patients and healthcare professionals fewer options.

Economic Constraints: Many patients may find it difficult to obtain necessary prescriptions due to financial restraints, particularly in rural or low-income settings.

Limited Awareness and Education: Inadequate knowledge about infectious diseases and the value of preventative measures can lead to delayed diagnosis and treatment, which might affect the market's demand for pharmaceuticals.

Healthcare Policies and Regulatory Landscape

The Drug Administration of Vietnam (DAV) and the Ministry of Health (MOH) must approve any pharmaceutical imports into the region. To obtain approval from the Drug Administration of Vietnam, the manufacturer (applicant) must submit an application dossier containing all the details and supporting evidence required by the Regulation on Registration of Drugs. Clinical study conduct can be difficult in Vietnam due to a lack of appropriate facilities and trained investigators, which could delay the clearance procedure.

Competitive Landscape

Key Players:

Mekophar
Hau Giang Pharmaceutical
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.